No Data
US Stock MarketDetailed Quotes
AKTX Akari Therapeutics
Watchlist
3.8500
+0.2300+6.35% Close 09/25 16:00 ET
3.9800High3.3097Low39.47KVolume
3.6000Open3.6200Pre Close150.34KTurnover1.40%Turnover RatioLossP/E (TTM)19.46MMarket Cap13.400052wk HighLossP/E (Static)5.06MShares2.808052wk Low10.69P/B10.86MFloat Cap5000.0000Historical High--Dividend TTM2.82MShs Float2.8000Historical Low--Div YieldTTM18.52%Amplitude3.8080Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Akari Therapeutics Company
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.
News
Pharma Stocks Lead European Equities Traded in the US as American Depositary Receipts Lower Thursday
Pharma stocks led European equities traded in the US as American depositary receipts lower Thursday, falling 0.8% to 1,207.09 on the S&P Europe Select ADR Index. From continental Europe, the gainers w
Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit
BOSTON and LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) ("Akari" or the "Company"), a late-stage biotechnology company developing advanced therapies for autoimmu
Bank, Oil Stocks Help Lift European Equities Traded in the US as American Depositary Receipts Higher Tuesday
Bank and oil stocks helped lift European equities traded in the US as American depositary receipts in Tuesday trading, rising 0.20% to 1,211.46 on the S&P Europe Select ADR Index. From continental Eur
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--